Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.
about
Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.Biosynthesis of type VI collagen by glioblastoma cells and possible function in cell invasion of three-dimensional matrices.COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.Fibroblast heterogeneity in the cancer wound.Proteolytic modification of laminins: functional consequences.Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells.Laminin-111-derived peptides and cancer.TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cellsRemodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.Integrins and extracellular matrix: a novel mechanism of multidrug resistance.Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysisDevelopment of seven new human prostate tumor xenograft models and their histopathological characterization.Tumorigenic conversion of immortal human keratinocytes through stromal cell activation.Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype.Prognosis of treatment response (pathological complete response) in breast cancer.Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblastsIncreased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells.3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in miceOutgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancerInhibition of angiogenesis, tumour growth and experimental metastasis of human fibrosarcoma cells HT1080 by a multimeric form of the laminin sequence Tyr-Ile-Gly-Ser-Arg (YIGSR)Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II.Therapeutic resistance in lung cancer.Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice.The laminin-derived peptide YIGSR (Tyr-Ile-Gly-Ser-Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID miceBrainstem and other malignant gliomas: II. Possible mechanisms of brain infiltration by tumor cells.Metastasis prevention by targeting the dormant niche.The tumor microenvironment is a dominant force in multidrug resistance.Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells.Laminin-111 Peptides Conjugated to Fibrin Hydrogels Promote Formation of Lumen Containing Parotid Gland Cell ClustersYAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.Syntenin increases the invasiveness of small cell lung cancer cells by activating p38, AKT, focal adhesion kinase and SP1.Therapeutic targeting of tumor-stroma interactions.Pro-metastatic tumor-stroma interactions in breast cancer.The dormancy dilemma: quiescence versus balanced proliferation.25th anniversary article: Designer hydrogels for cell cultures: a materials selection guide.Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.Liver metastases: Microenvironments and ex-vivo models.Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection.Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
P2860
Q27329810-C1C01AA0-A8DC-4DB4-9FD6-5124A972F8B9Q33210247-1360DC09-BCF2-4BA5-A56B-BA52D3956AAEQ33624642-3E060A6F-495A-45E8-AC33-4815057484E4Q33964324-0A786073-5365-4942-B30D-44779768CA47Q34071967-3C5FC9F7-A8B8-4341-AE13-6EE36147F3E9Q34166339-B5DBC116-83DA-4A06-8C5E-031921F92CD3Q34646764-B897AD32-E81D-47BB-B4BD-E0D50420C3CAQ34737426-5891C231-83C8-4183-A05E-D886E4FC0E66Q35087966-06E9FE6C-7568-480D-B02A-C1ED4A2E64D4Q35089143-D10F999F-E67F-42EB-9C8E-B37F6903EB3CQ35350250-5B954998-BA3B-448B-B55B-4DA22DE5F3D1Q35782119-50B1B36D-5C77-4B57-B217-85C6A72CB3A1Q35787577-31997527-E58F-44EA-8D26-6F0C3BD4F72AQ35833651-9C3A40A0-9DB8-4FE8-967F-DF9F9999CA52Q35971135-A8A083A4-4EF4-45C0-959C-73A6A93B2A12Q35977847-11220E6F-3D34-4635-9D6B-83397D70503BQ35994429-68FBD47D-EF3B-4AE7-9737-4ACC0EDFD6DBQ36037262-7352F4A3-6F70-48FE-A48C-CDE034D52D4CQ36081260-C28C6F59-029C-4FCE-8C02-495F81694470Q36081930-CE8D2F3E-973F-4063-BB4A-2F96CFACFBB7Q36134587-13D211CF-4D98-4F9D-800C-DC33B85CB773Q36136076-28C66AEF-902B-4BEB-8380-B5B6B75E20A6Q36609767-6A4858B2-4BB5-47E5-AAC2-51CEC7EC859DQ36617578-5D05B310-16A1-4F96-900D-E4938F106087Q36620637-4B592CB5-D75E-493E-B78C-E84D37C24358Q36754502-E3C1EEDA-3BD0-4993-8549-259F2344F007Q36829245-41B44F0B-099A-4173-ABEE-387FB1AE42CBQ36856829-0C548E47-DF6F-4D4B-918B-367F871A23C6Q37221221-B61F255B-874E-4AE1-B398-A53EDD1172FAQ37268369-FDF5698A-C5E1-4676-A9A4-E8A13BFD8080Q37544346-94386A5F-336F-4CC3-9E24-5717BAD12358Q37679452-1E84CBCF-A253-4C34-B2F2-8BDD477CEDC9Q37851151-A037B887-9907-48A6-BEC9-A04572B1841EQ38059502-929061CB-CDA3-487A-AB6F-F42D370326E0Q38116507-A6834235-621C-4187-A7D6-41307731DFBBQ38162420-8FD34EB6-6111-43A2-ADFC-A362790883DDQ38309552-879C3DF0-8E1A-449B-BB32-5C98EF4341A5Q38889829-32D00677-6986-4527-83D4-3F86EEFC1796Q39346450-C61E2E0A-E825-4B1D-A985-B3D22B4241FDQ40059658-91EF3B2E-E167-4DEF-BC76-58CE5E7D03C2
P2860
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Reconstituted basement membran ...... l cell lung cancer cell lines.
@ast
Reconstituted basement membran ...... l cell lung cancer cell lines.
@en
type
label
Reconstituted basement membran ...... l cell lung cancer cell lines.
@ast
Reconstituted basement membran ...... l cell lung cancer cell lines.
@en
prefLabel
Reconstituted basement membran ...... l cell lung cancer cell lines.
@ast
Reconstituted basement membran ...... l cell lung cancer cell lines.
@en
P2093
P2860
P356
P1476
Reconstituted basement membran ...... l cell lung cancer cell lines.
@en
P2093
P2860
P304
P356
10.1073/PNAS.87.17.6698
P407
P577
1990-09-01T00:00:00Z